Executive Summary
ARGX-118 is a Galectin-10 targeting molecule entering Phase 1 in 2026 as part of argenx's three new Phase 1 programs.
ARGX-118
Target: Galectin-10
Full NameGalectin-10
Mechanism of Action
Target Biology[Corp '26 S22]
No target biology data available.
Clinical Data
No clinical trial data available.
Market Opportunity
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| Phase 1 initiation | 2026 | medium | First-in-human safety and PK data | — |